FibroBiologics Inc. Commo... (FBLG)
NASDAQ: FBLG
· Real-Time Price · USD
0.94
0.09 (10.04%)
At close: Jun 06, 2025, 3:59 PM
0.97
3.53%
After-hours: Jun 06, 2025, 05:54 PM EDT
Company Description
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States.
It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing.
The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers.
FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
FibroBiologics Inc. Common Stock

Country | United States |
IPO Date | Feb 1, 2024 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 13 |
CEO | Peter O'Heeron |
Contact Details
Address: 455 East Medical Center Boulevard Houston, Delaware United States | |
Website | https://www.fibrobiologics.com |
Stock Details
Ticker Symbol | FBLG |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001958777 |
CUSIP Number | 31573L105 |
ISIN Number | US31573L1052 |
Employer ID | 86-3329066 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Peter O'Heeron | Founder, Chairperson & Chief Executive Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 27, 2025 | 4 | Filing |
May 14, 2025 | 10-Q | Quarterly Report |
May 05, 2025 | 8-K | Current Report |
Apr 23, 2025 | ARS | Filing |
Apr 23, 2025 | DEFA14A | Filing |
Apr 23, 2025 | DEF 14A | Filing |
Mar 31, 2025 | 10-K | Annual Report |
Mar 28, 2025 | 4 | Filing |
Mar 28, 2025 | 4 | Filing |
Mar 28, 2025 | 4 | Filing |